These differences likely reflect both stronger trial design and larger study populations, as well as the fact that HFpEF with obesity is a metabolically driven phenotype, where GLP-1 receptor agonists directly target central mechanisms of disease. The gene discussed is GLP1R; the disease is obesity disorder.